From Wikipedia, the free encyclopedia
Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis that is prepared from a strain of the attenuated (weakened) live bovine tuberculosis bacillus, Mycobacterium bovis, that has lost its virulence in humans by being specially cultured in an artificial medium for years. The bacilli have retained enough strong antigenicity to become a somewhat effective vaccine for the prevention of human tuberculosis. At best, the BCG vaccine is 80% effective in preventing tuberculosis for a duration of 15 years, however, its protective effect appears to vary according to geography.
The history of BCG is tied to that of small pox. Jean Antoine Villemin first recognised bovine tuberculosis in 1854 and transmitted it, and Robert Koch first distinguished Mycobacterium bovis from Mycobacterium tuberculosis. After the success of vaccination in preventing small pox, scientists thought to find a corollary in tuberculosis. A parallel was drawn between bovine tuberculosis and cow pox, and it was hypothesised that infection with bovine tuberculosis might protect against infection with human tuberculosis. In the late 19th century, clinical trials using M. bovis were conducted in Italy with disastrous results, because M. bovis was found to be just as virulent as M. tuberculosis.
Albert Calmette, a French bacteriologist, and his assistant and later colleague, Camille Guérin, a veterinarian, were working at the Pasteur Institute in Lille in 1908. Their work included the subculturing of virulent strains of the tuberculosis bacillus and the testing of different culture media. They noted that a glycerin-bile-potato mixture grew bacilli that seemed less virulent. They changed the course of their research to see if repeated subculturing would produce a strain that was attenuated to be considered for use as a vaccine. Throughout World War I, the research continued until 1919 when the now non-virulent bacilli were unable to cause tuberculosis disease in research animals. They transferred to the Paris Pasteur Institute in 1919. In 1921, the BCG vaccine was first used in humans.
Public acceptance was slow and one disaster in particular did much to harm public acceptance of the vaccine. In Lubeck, 240 infants were vaccinated in the first 10 days of life; almost all developed tuberculosis and 72 infants died. It was subsequently discovered that the BCG administered had been contaminated with a virulent strain that was being stored in the same incubator, and led to legal action being taken against the manufacturers of BCG.
In 1928 it was adopted by the Health Committee of the League of Nations. However, because of opponents of vaccination, it was not widely used until after World War II. From 1945 to 1948, relief organizations (International Tuberculosis Campaign or Joint Enterprises) vaccinated over 8 million babies in eastern Europe and prevented the predicted increase of TB after a major war.
The vaccine proved to be the safest and the most widely used vaccine. The vaccine is very efficacious against tuberculous meningitis in the pediatric age group, but its efficacy against pulmonary tuberculosis appears to be variable. As of 2006, a few countries do not use BCG for routine vaccination, and the USA and the Netherlands have never used it routinely. In the United States, BCG vaccination is not routinely given to adults because it is felt that having a reliable Mantoux test, and being able to accurately detect active disease, is more beneficial to society than vaccinating against a relatively rare (in the US) condition.
 Variable efficacy
The most controversial aspect of BCG is the variable efficacy found in different clinical trials that appears to depend on geography. Clinical trials conducted in the UK have consistently shown a protective effect of 60 to 80%, but trials conducted elsewhere have shown no protective effect, and efficacy appears to fall the closer one gets to the equator.
The first large scale trial evaluating the efficacy of BCG was conducted from 1956 to 1963 and involved almost 60,000 school children who received BCG at the age of 14 or 15; this study showed an efficacy of 84% up to 5 years after immunization. However, a US Public Health Service trial of BCG in Georgia and Alabama published in 1966 showed an efficacy of only 14%, and did much to convince the US that it did not want to implement mass immunisation with BCG. A further trial conducted in South India and published in 1979 (the "Chingleput trial"), showed no protective effect.
The duration of protection of BCG is not clearly known. In those studies that have shown a protective effect, the data is inconsistent. The MRC study showed that protection waned to 59% after 15 years and to less than zero after 20 years; a study looking at native Americans immunised in the 1930's found evidence of protection even 60 years after immunisation with only a slight waning in efficacy.
BCG seems to have its greatest effect in preventing miliary TB or TB meningitis, for which reason, it is still extensively used even in countries where efficacy against pulmonary tuberculosis is nil.
 Reasons for variable efficacy
The reasons for the variable efficacy of BCG in different countries is difficult to understand. A number of possible reasons have been proposed but none have been proven.
- Background frequency of exposure to tuberculosis It has been hypothesised that in areas with high levels of background exposure to tuberculosis, every susceptible individual is already exposed prior to BCG, and that the natural immunising effect of background tuberculosis then appears to wipe out any benefit of BCG.
- Genetic variation in BCG strains There is genetic variation in the BCG strains used and this may explain the variable efficacy reported in different trials.
- Genetic variation in populations Difference in genetic make-up of different populations may explain the difference in efficacy. The Birmingham BCG trial was published in 1988. The trial was based in Birmingham, UK, and examined children born to families who originated from the Indian subcontinent (where vaccine efficacy had previously been shown to be zero). The trial showed a 64% protective effect, which is very similar to the figure derived from other UK trials, thus refuting the genetic variation hypothesis.
- Interference by non-tuberculous mycobacteria One hypothesis is that the presence in the environment of mycobacteria other than members of the M. tuberculosis complex are able to elicit an immune response in the population being studied. The hypothesis is then that BCG is unable to elicit a further immune response, because the population has already built up a natual immune response to mycobacteria. Whether this natural immune response is protective is again debatable. This hypothesis was first made by Palmer and Long.
- Interference by concurrent parasitic infection Another hypothesis is that simultaneous infection with parasites changes the immune response to BCG, making it less effective. A Th1 response is required for an effective immune response to tuberculous infection; one hypothesis is that concurrent infection with various parasites produces a simultaneous Th2-response which blunts the effect of BCG.
Tuberculosis The main use of BCG is for vaccination against tuberculosis. It is recommended that the BCG vaccination be given intradermally by a nurse skilled in the technique. Having had a previous BCG vaccination is a cause of a false positive Mantoux test, although a very high-grade reading is usually due to active disease.
The age and frequency that BCG is given has always varied from country to country.
- United States The US has never used mass immunisation of BCG, relying instead on the detection and treatment of latent tuberculosis.
- United Kingdom The UK introduced universal BCG immunisation in 1953 and until 2005, the UK policy was to immunise all school children at the age of 13, and all neonates born into high risk groups. BCG was also given to protect people who had been exposed to tuberculosis. The peak of tuberculosis incidence is in adolescence and early adulthood, and the evidence from the MRC trial was that efficacy lasted only 15 years at most. Styblo and Meijer argued that neonatal immunisation protected against miliary TB and other non-contagious forms of TB and not pulmonary TB which was a disease of adults, and that mass immunisation campaigns with BCG would therefore not be expected to have a significant public health impact. For these and other reasons, BCG was therefore given to time with the peak incidence of pulmonary disease. Routine immunisation with BCG was withdrawn in 2005 because of falling cost-effectiveness: whereas in 1953, 94 children would have to be immunised to prevent one case of TB, by 1988, the annual incidence of TB in the UK had fallen so much that 12,000 children would have to immunised to prevent one case of TB.
- India India introduced BCG mass immunisation in 1948, the first non-European country to do so.
- Brazil Brazil introduced universal BCG immunisation in 1967-1968, and the practice is uphold until now.
- Other countries In the UK, BCG was only ever given once (as there is no evidence of additional protection from more than one vaccination), but in some countries such as the former USSR, BCG was given regularly throughout life. In Singapore, BCG was given at birth and again at the age of 12. From 2005, this policy was changed to once only at the age of 12.
 Method of administration
Except in neonates, a tuberculin skin test should always be done before administering BCG. A reactive tuberculin skin test is a contraindication to BCG. If someone with a positive tuberculin reaction is given BCG, there is a high risk of severe local inflammation and scarring. It is a common misconception that tuberculin reactors are not offered BCG because "they are already immune" and therefore do not need BCG. People found to have reactive tuberculin skin tests should be screened for active tuberculosis.
BCG is given as a single intradermal injection at the insertion of the deltoid. If BCG is accidentally given subcutaneously, then a local abscess may form (a BCG-oma) that may ulcerate and often requires treatment with antibiotics.
BCG immunisation leaves a characteristic raised scar that is often used as proof of prior immunisation. The scar of BCG immunisation must be distinguished from that of small pox vaccination which it may resemble.
 Other uses
- Leprosy: BCG has a small protective effect against leprosy of around 26%, although it is not used specifically for this purpose.
- Cancer Immunotherapy: BCG is useful in the treatment of superficial forms of bladder cancer. Since the late 1980s evidence has become available that instillation of BCG into the bladder is an effective form of immunotherapy in this disease. While the mechanism is unclear, it appears that a local immune reaction is mounted against the tumor. Immunotherapy with BCG prevents recurrence in up to ⅔ of cases of superficial bladder cancer. BCG also finds use for immunotherapy of colorectal cancer and for the treatment of equine sarcoid in horses.
- Diabetes, Type I: Clinical trials based on the work of Denise Faustman use BCG to induce production of TNF-α which can kill the T-cells responsible for Type 1 diabetes. Studies using mice have shown that a similar treatment results in a permanent cure for about a third of the test subjects.
 Adverse effects
BCG is one of the most widely used vaccines in the world, with an unparalleled safety record. BCG immunisation causes pain and scarring at the site of injection. The main adverse effect are keloids or large, ugly scars. The insertion of deltoid is most frequently used because the local complication rate is smallest when that site is used. If given subcutaneously, BCG causes a local skin infection that may spread to the regional lymph nodes causing a suppurative lymphadenitis.
If BCG is accidentally given to an immunocompromised patient (e.g., an infant with SCID), it can cause disseminated or life-threatening infection. The documented incidence of this happening is less than 1 per million immunisations given.
 Other tuberculosis vaccines
 See also
- Heaf test
- Mantoux test
- Philip D'Arcy Hart
- BCG disease outbreak in Finland in the 2000's
- ^ Fine PEM, Carneiro IAM, Milstein JB, Clements CJ. (1999). Issues relating to the use of BCG in immunisation preogrammes. Geneva: WHO.
- ^ Rosenthal SR. (1957). BCG vaccination against tuberculosis. Boston: Litte, Brown & Co..
- ^ Colditz GA, Brewer TF, Berkey CS, et al. (1994). "Efficacy of BCG Vaccine in the Prevention of Tuberculosis". J Am Med Assoc 271: 698–702.
- ^ Hart PD, Sutherland I. (1977). "BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Final Report of the Medical Research Council". Brit Med J 2: 293–95.
- ^ Comstock GW, Palmer CE. (1966). "Long-term results of BCG in the southern United States". Am Rev Resp Dis 93 (2): 171–83.
- ^ Tuberculosis Prevention Trial (1979). "Trial of BCG vaccines in south India for tuberculosis prevention". Indian J Med Res 70: 349–63.
- ^ Aronson NE, Santosham M, Comstock GW, et al. (2004). "Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study". JAMA 291 (17): 2086–91. PMID 15126436.
- ^ Rodrigues LC, Diwan VK, Wheeler JG (1993). "Protective Effect of BCG against Tuberculous Meningitis and Miliary Tuberculosis: A Meta-Analysis". Int J Epidemiol 22: 1154–58.
- ^ Brosch R, Gordon SV, Garnier T, Eiglmeier K, et al. (2007). "Genome plasticity of BCG and impact on vaccine efficacy". Proc Natl Acad Sci. DOI:10.1073/pnas.0700869104.
- ^ Packe GE, Innes JA. (1988). "Protective effect of BCG vaccination in infant Asians: a case-control study" 63: 277–281.
- ^ (1966) "Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis.". Am Rev Respir Dis: 553–68.
- ^ Rook GAW, Dheda K, Zumla A. (2005). "Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?". Vaccine 23 (17–18): 2115–20. DOI:10.1016/j.vaccine.2005.01.069.
- ^ Styblo K, Meijer J. (1976). "Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem". Tubercle 57: 17–43.
- ^ Mahler HT, Mohamed Ali P (1955). "Review of mass B.C.G. project in India". Ind J Tuberculosis 2 (3): 108–16.
- ^ Setia MS, Steinmaus C, Ho CS, Rutherford GW. (2006). "The role of BCG in prevention of leprosy: a meta-analysis". Lancet Infect Dis 6 (3): 162–70. PMID 16500597.
- ^ Lamm DL, Blumenstein BA, Crawford ED, et al. (1991). "A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder". N Engl J Med 325: 1205–9. PMID 192220.
- ^ Mosolits S, Nilsson B, Mellstedt H. (2005). "Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials". Expert Rev Vaccines 4: 329–50. PMID 16026248.
- ^ Centers for Disease Control and Prevention (1996). "The role of BCG vaccine in the prevention and control of tuberculosis in the United Staes: a joint statemnt of the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices". MMWR Recomm Rep 45 (RR-4): 1–18. PMID 8602127.
- Thomas Dormandy (1999). The White Death: A History of Tuberculosis. Chapter 30 Vaccines. ISBN 0814719279 HB - ISBN 1852853328 PB
- Comstock GW. The International Tuberculosis Campaign: a pioneering venture in mass vaccination and research. Clin Infect Dis 1994;19(3):528-40. PMID 95110996.
 External links
- Frequently Asked Questions about BCG Professor P D O Davies, Tuberculosis Research Unit, Cardiothoracic Centre, Liverpool, UK.